Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 02:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Start: 2015-07-21. Completion: 2017-11-09 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
liraglutide (drug)
Where the study takes place — 47 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Novo Nordisk Investigational Site Annaka-shi, Gunma, Japan Site recruitment: Not reported
Chitose, Hokkaido, Japan
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Start: 2016-08-18. Completion: 2017-09-03 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
NNC9204-0530 (drug)
liraglutide (drug)
placebo (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Novo Nordisk Investigational Site Tempe, Arizona, United States Site recruitment: Not reported
Novo Nordisk Investigational Site Lincoln, Nebraska, United States Site recruitment: Not reported
Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sponsor
Novo Nordisk A/S
Countries with listed sites
Germany
Registry dates and results
Start: 2018-02-05. Completion: 2018-05-24 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
NNC9204-1513 (drug)
Glucagon (drug) — also listed as: GlucaGen®
Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Novo Nordisk Investigational Site Berlin, Germany Site recruitment: Not reported
Start: 2017-06-06. Completion: 2018-10-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Glucagon (drug)
Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Toronto General Hospital Toronto, Ontario, Canada Site recruitment: Recruiting
Start: 2013-11. Completion: 2015-01 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Nasal Glucagon (drug) — also listed as: AMG504-1, LY900018
Intramuscular Glucagon (drug) — also listed as: GlucaGen HypoKit
Where the study takes place — 7 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Barbara Davis Center for Diabetes Aurora, Colorado, United States Site recruitment: Not reported
Yale University New Haven, Connecticut, United States Site recruitment: Not reported
University of Florida Gainesville, Florida, United States Site recruitment: Not reported
Nemours Children's Clinic Jacksonville, Florida, United States Site recruitment: Not reported
Riley Hospital for Children Indiana University Health Indianapolis, Indiana, United States Site recruitment: Not reported
University of Minnesota Minneapolis, Minnesota, United States Site recruitment: Not reported
UPA Buffalo Buffalo, New York, United States Site recruitment: Not reported
Start: 2017-05-31. Completion: 2018-04-05 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
LY3325656 (drug)
Placebo (drug)
Liraglutide (drug)
Sitagliptin (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. Singapore, Singapore Site recruitment: Not reported
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. Singapore, Singapore Site recruitment: Not reported
Start: 2013-01. Completion: 2015-01 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Closed loop with sensor and Insulin (drug) — also listed as: Novolog
Closed loop with sensor, Insulin and Liraglutide (drug) — also listed as: Victoza
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Albert Einstein College of Medicine West Campus CRC The Bronx, New York, United States Site recruitment: Not reported
Start: 2012-09. Completion: 2017-08 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
GLP-1 (biological) — also listed as: Glucagon-like peptide-1
Intravenous saline (biological)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Uppsala University Uppsala, Uppsala County, Sweden Site recruitment: Not reported
Start: 2014-12. Completion: 2015-08 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
liraglutide (drug) — also listed as: Victoza 6 mg/ml solution for injection in pre-filled pen
Testosterone (drug) — also listed as: Androtop gel
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Medical Center Ljubljana Ljubljana, Slovenia Site recruitment: Not reported
Start: 2017-04-01. Completion: 2017-12-28 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Bihormonal Bionic Pancreas (device)
Insulin Only Bionic Pancreas (device)
Monitored for Hypoglycemia (other)
Not Monitored for Hypoglycemia (other)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
MGH Diabetes Research Center Boston, Massachusetts, United States Site recruitment: Not reported
Start: 2016-06-29. Completion: 2018-06 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
RYGB (procedure)
GLP-1 (drug) — also listed as: gut hormone
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Dept.Clinical and Experimental Medicine.Section of Diabetes. Pisa, Italy Site recruitment: Not reported
Start: 2015-11-19. Completion: 2017-04-18 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide (drug) — also listed as: Victoza
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Bispebjerg University Hospital Copenhagen, Copenhagen Northwest, Denmark Site recruitment: Not reported
Start: 2017-07-01. Completion: 2017-12-10 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Placebo Oral Tablet (drug)
Metformin (drug)
Saline (drug)
Exendin (9-39) (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Center for Diabetes Research Gentofte Municipality, Copenhagen, Denmark Site recruitment: Not reported
Start: 2016-03-16. Completion: 2017-02-27 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
liraglutide (drug)
placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Novo Nordisk Investigational Site Hellerup, Denmark Site recruitment: Not reported
Start: 2015-03. Completion: 2021-07 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
GLP-1 (drug) — also listed as: GLP-1 (7-36) amide
placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Papworth Hospital Cambridge, Cambridgeshire, United Kingdom Site recruitment: Not reported
Start: 2018-06-01. Completion: 2019-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Oral glucose tolerance test (other)
Liquid mixed meal test (other)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Gastrointestinal Surgery, Righospitalet Copenhagen, Capital, Denmark Site recruitment: Recruiting
Start: 2013-03-13. Completion: 2015-05 (may be estimated). No results posted in this registry response.
Products and interventions (8)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Control (drug) — also listed as: No Peptide or Atropine
Xenin-25 without atropine (drug) — also listed as: xenin without atropine
GIP without atropine (drug)
Placebo with atropine (drug) — also listed as: Albumin (no peptide) with atropine
Xenin-25 with atropine (drug) — also listed as: xenin and atropine
GIP with atropine (drug) — also listed as: GIP and atropine
GIP plus Xenin-25 without atropine (drug) — also listed as: GIP plus xenin without atropine
GIP plus Xenin-25 with atropine (drug) — also listed as: GIP plus xenin with atropine
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Washington University School of Medicine St Louis, Missouri, United States Site recruitment: Not reported
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Catholic University School of Medicine Rome, Italy Site recruitment: Not reported
Start: 2016-06. Completion: 2018-10 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Tablet Sitagliptin 100mg (evening before and morning of experiments) (drug)
Intestinal Fructose administration (other)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Department of Surgery C, Rigshospitalet Copenhagen, Denmark Site recruitment: Recruiting
Start: 2014-08. Completion: 2017-04 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide combined with metformin (drug) — also listed as: Victoza®, Novo Nordisk
Insulin glargine combined with metformin (drug) — also listed as: Lantus®, Sanofi
Sitagliptin combined with metformin (drug) — also listed as: Januvia®, Merck & Co. Inc.
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
The Third Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China Site recruitment: Not reported
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.